Soluble Antigen Array Displaying Proinsulin(F25D) Selectively Targets Anti-insulin B Cells without Hormonal Effects
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01428 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Grant M Downes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bioengineering Graduate Program, University of Kansas, Lawrence, Kansas 66045, United States. Hauptthemen laut MEDLINE: Proinsulin, B-Lymphocytes, Insulin. Die Arbeit nennt 61 Literaturangaben. Gefördert von: National Institute of Allergy and Infectious Diseases, University of Kansas, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Antigen presentation to autoreactive T cells in the pancreatic islets by dendritic cells and B lymphocytes is paramount to the pathogenesis of Type 1 diabetes (T1D). Immunosuppressive therapies, such as rituximab (anti-CD20) and teplizumab (anti-CD3), can delay T1D onset; however, risks associated with B or T cell depletion, such as an increased susceptibility to infections, are considerable. Antigen-specific immunotherapy (ASIT) offers a more targeted approach to suppress or delete the autoreactive cells, specifically recognizing autoantigens associated with disease. Soluble antigen arrays (SAgAs) are a platform consisting of a hyaluronic acid (HA) backbone and multiple copies of the autoantigen to selectively suppress autoreactive B cells and T cells. Here, a new SAgA was developed by conjugating a mutated proinsulin antigen (proinsulin(F25D)) to HA (SAgAM-PI(F25D)) to avoid glycemic activity while retaining the ability to target anti-insulin antibodies and B cells. SAgAM-PI(F25D) had a pronounced reduction in insulin receptor-β activity and lacked glycemic activity in vivo. Furthermore, this SAgA successfully bound a disease-relevant monoclonal anti-insulin antibody with low nanomolar binding affinity and murine transgenic (Tg125) B cells specific for human insulin. This collection of data demonstrated the avoidance of glycemic effects of proinsulin SAgAs while retaining specificity to anti-insulin antibody and insulin-binding B cells, thus highlighting the potential as a candidate for intervening in T1D as an ASIT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioengineering Graduate Program, University of Kansas, Lawrence, Kansas 66045, United States.
- Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri 63130, United States.
- Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047, United States.
- Department of Medicine, Division of Allergy and Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri 63110, United States.
- Columbia Center for Translational Immunology, Department of Medicine and Naomi Berrie Diabetes Center, Columbia University Irving Medical Center, New York, New York 10032, United States.
- Department of Chemical and Petroleum Engineering, University of Kansas, Lawrence, Kansas 66045, United States.
ORCID-Profile: Grant M Downes, Kyle D Apley, Camillo Bechi Genzano, Cory J Berkland
Förderung
- National Institute of Allergy and Infectious Diseases
- University of Kansas
- National Institute of General Medical Sciences
Zitieren
APA
Downes, G. M., Apley, K. D., Hu, G., Griffith, A. S., Bechi Genzano, C., Silva, C. R., Kendall, P. L., Creusot, R. J., & Berkland, C. J. (2026). Soluble Antigen Array Displaying Proinsulin(F25D) Selectively Targets Anti-insulin B Cells without Hormonal Effects. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01428
Vancouver
Downes GM, Apley KD, Hu G, Griffith AS, Bechi Genzano C, Silva CR, et al. Soluble Antigen Array Displaying Proinsulin(F25D) Selectively Targets Anti-insulin B Cells without Hormonal Effects. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01428
BibTeX
@article{Downes2026,
author = {Downes, Grant M and Apley, Kyle D and Hu, Gang and Griffith, Amber S and Bechi Genzano, Camillo and Silva, Colin R and Kendall, Peggy L and Creusot, Remi J and Berkland, Cory J},
title = {Soluble Antigen Array Displaying Proinsulin(F25D) Selectively Targets Anti-insulin B Cells without Hormonal Effects},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01428}
}
EUVIMED